Rationale: Endothelial cell-specific molecule 1 (Esm1) is a secreted protein thought to play a role in angiogenesis and inflammation. However, there is currently no direct in vivo evidence supporting a function of Esm1 in either of these processes.
ndothelial cell-specific molecule 1 (Esm1) is a dermatan sulfate proteoglycan that is expressed and secreted by endothelial cells (ECs) and renal epithelia. 1 Its expression is regulated both by inflammatory cytokines (interleukin-1β, tumor necrosis factor-α, interferon-γ) 2, 3 and proangiogenic factors (vascular endothelial growth factor-A [VEGF-A] and VEGF-C). 4, 5 Several lines of evidence suggest that Esm1 plays a role in inflammation. For instance, it was shown in vitro that Esm1 interacts with LFA-1 (lymphocyte functionassociated antigen 1) and that this inhibits the adhesion of leukocytes to intercellular adhesion molecule 1 (ICAM1), which suggests a negative role in leukocyte extravasation during inflammation. 6 Moreover, Esm1 plasma levels have been reported to be increased in pathological situations such as sepsis 7 and several cancer types where it is a marker of poor prognosis. [8] [9] [10] [11] [12] [13] [14] It has also been described that Esm1 increases proliferation and survival of tumor cells, [15] [16] [17] which underlies the fact that overexpression of Esm1 in tumorigenic cells is sufficient to induce tumor growth. Concurrently, blocking of Esm1 function through the use of antibodies or small interfering RNA has been described to reduce tumor growth and evasiveness. 15, 16 It has also been suggested that the levels of Esm1 directly correlate with tumor angiogenesis. 17 In vitro experiments showed that Esm1 enhances the promigratory and proliferative effects of VEGF on lymphatic ECs. 5 Esm1 expression is highly enriched in retinal endothelial tip cells 18, 19 and in tumor endothelium, 9, 14, 20 which makes it a useful marker for neoangiogenesis. However, the analysis of angiogenesis through the use of matrigel plugs in vivo concluded that Esm1 had no effect on angiogenesis. 4 Thus, the exact function of Esm1 in vivo and the underlying molecular mechanisms remain elusive. August 29, 2014 In this study, we have used Esm1 knockout (Esm1 KO ) mice to study the function of the gene product in vivo. We show that Esm1 is required for optimal response to VEGF stimuli. Esm1 is strongly and exclusively expressed by endothelial tip cells during retinal angiogenesis. Esm1-deficient sprouts emitted less filopodia and displayed decreased phospho-Erk1/2 (pErk1/2) levels, which resulted in reduced vascular progression. Esm1 was also previously implicated in inflammation where it was thought to inhibit leukocyte adhesion to intercellular adhesion molecule 1 in vitro. Surprisingly, we found that Esm1 does not affect leukocyte rolling and adhesion in vivo, instead it positively regulates leukocyte extravasation at the endothelial transmigration level. In addition, Esm1 is required for optimal VEGF-induced vascular permeability (VP). Mechanistically, we show that Esm1 binds directly to fibronectin and thereby displaces fibronectin-bound VEGF-A 165 . This leads to increased bioavailability of local VEGF-A 165 and increased levels of VEGF signaling. Importantly, Esm1 also modulates pathological angiogenesis and especially VP.
Esm1
KO mice presented a modest decrease in tumor angiogenesis, whereas cerebral edema, attributable to ischemic strokeinduced VP, was reduced by 50%. Thus, Esm1 is both a target and modulator of VEGF signaling in ECs with roles in the regulation of angiogenesis, inflammation, and permeability.
Methods
An expanded Methods section is available in the Online Data Supplement.
Mutant Mice, Inducible Genetic Experiments, and Pharmacological Inhibition
EC-specific deletion of Vegfr2 in the postnatal vasculature was achieved by interbreeding Vegfr2 floxed mice 21 with Cdh5(PAC) CreERT222 transgenic mice. One hundred micrograms of tamoxifen (Sigma, T5648; 2 mg/mL) was administered intraperitoneally in every littermate at postnatal day 3 (P3), P4, and P5. For the pharmacological inhibition of VEGF receptor (VEGFR) signaling in vivo, we administered subcutaneous injections of the vehicle (dimethyl sulfoxide), VEGFR2 inhibitor (SU5416, Sigma; 25 μg/g), VEGFR3 inhibitor (MAZ51, Sigma; 10 μg/g), or MEK1/2 (mitogen-activated protein kinase kinase) inhibitor (U0126, Cell Signaling; 25 μg/g) at P5 and 8 hours before dissecting the animals. Anti-VEGF-A (50 mg/kg; Genentech, G6-31) or control IgG antibodies (Jackson ImmunoResearch) were injected intraperitoneally every day from P4 to P6.
In Vivo Permeability and Inflammation Assays
VEGF-A 121 -, VEGF-A 165 -, and histamine-induced VP in the mouse dorsal skin and interleukin-1β-induced peritonitis and neutrophil recruitment in the cremaster muscle were performed as previously described. 23, 24 All animal procedures were performed in accordance with national and regional laws and regulations and were approved by animal ethics committees. All efforts were made to minimize suffering of the mice.
Esm1-FLAG Cloning, Synthesis, and Immunoprecipitation
C-terminal FLAG-tagged mouse Esm1 was cloned. Human embryonic kidney 293 cells were transfected with the cloned construct or empty vector alone. Cells were then incubated in serum-free medium for 48 hours. The culture supernatant was then collected, filtered, and incubated on a monolayer of human umbilical vein ECs (HUVECs) for 45 minutes, at 37°C, after which they were washed and then lysed. Esm1-FLAG bound to HUVEC-derived proteins was immunoprecipitated with anti-Flag M2 agarose. Samples were sent for mass spectrometry analysis.
Solid Phase Binding Assays
Binding of Esm1, VEGF-A 165 , VEGF-A 121 , and platelet-derived growth factor-B (PDGF-BB) to fibronectin was shown by solid phase binding assay by ELISA as previously described.
25
VEGF-A 121 , VEGF-A 165 , and Esm1 ELISA Measurement of VEGF-A 121 and VEGF-A 165 in coating supernatants was achieved by using an ELISA kit for human VEGF (DVE00, R&D).
For measuring Esm1 levels in mouse serum, blood samples were centrifuged at 2000 rpm, 10 minutes at room temperature (r/t) and supernatant was collected. ELISA was performed as previously described. 26 Capture antibody used was goat anti-mouse Esm1 (AF1999 R&D), and the detection antibody was rat anti-mouse Esm1 (LIA0905 Lunginnov).
Results

Esm1 Is Highly Expressed by ECs With High VEGF Signaling
Esm1 mRNA was recently described to be specifically expressed in endothelial tip cells in the developing mouse retina. 18, 19 Immunostaining of P5 retinas confirmed that the secreted Esm1 protein is indeed marking distal vascular sprouts ( Figure 1A ). To check whether Esm1 is a universal tip cell marker, we analyzed the protein expression pattern of Esm1 in Lewis lung carcinoma tumors. Esm1 immunostaining was detected only in ECs, but its expression was not restricted to sprouting cells in tumor blood vessels. Instead, Esm1 protein was detected throughout the vasculature ( Figure 1B ).
Esm1 expression is positively regulated by VEGF-A in vitro and in tumor models, 4, 5, 27 and it has also been shown to be upregulated by VEGF-C in lymphatic ECs. 5 To confirm the influence of VEGF-A signaling on Esm1 expression under physiological conditions in vivo, we analyzed the lungs of mice in which the Vegfr2/Flk1 gene had been deleted in ECs or of animals treated with VEGF-A-blocking antibody. Esm1 transcript levels were prominently decreased in Vegfr2 mutants and after VEGF-A blockade ( Figure 1C) . Furthermore, P5 pups were treated with chemical compounds that inhibit the kinase domain of VEGFR2 (SU5416) and VEGFR3 (MAZ51). Expression of Esm1 was specifically and profoundly reduced by VEGFR2 inhibition but not by MAZ51 ( Figure 1D ). These results correlate well with the known expression patterns of VEGF-A and VEGF-C in the retina. VEGF-C, the main VEGFR3 ligand, is expressed by macrophages that are not exclusively localized at the angiogenic front, 28 whereas expression of VEGF-A, the main VEGFR2 ligand, is presented by astrocytes in the avascular, peripheral retina. 29 Accordingly, endothelial tip cells in the retina are more exposed to VEGF-A than ECs within the angiogenic plexus, which may account for the tip cell-specific expression of Esm1 in the retinal vasculature. On the contrary, Esm1 expression in most, if not all, tumor ECs but not vessels in the surrounding tissue, correlates with higher VEGF-A levels throughout the tumor. Thus, we conclude that Esm1 is not a general endothelial tip cell marker, but that its expression rather reflects high VEGF-A signaling levels ( Figure 1E ).
Retinal Vascular Outgrowth and Filopodia Emission Are Impaired in Esm1
KO Mice VEGF-A regulates Esm1 expression in vivo ( Figure 1C and 1D), suggesting that it might be implicated in angiogenesis. Therefore, we evaluated angiogenesis in control and Esm1 KO P5 retinas. The mutant vasculature showed a slight but significant decrease in vascular outgrowth (Figure 2A and 2D) indicative of impaired angiogenesis in Esm1 KO mice. This difference was not caused by general developmental delay because the weight of Esm1-deficient mutants was comparable with that of littermate controls ( Figure 2E ). Because Esm1 is secreted and may act on neighboring stalk cells, we questioned whether EC proliferation, which occurs mostly at the stalk cell level, was altered and the cause of the decreased vascular progression. We quantified retinal EC proliferation by immunostaining for phospho-histone-3, which labels mitotic cells. No significant difference was observed between Esm1 WT and Esm1 KO retinas ( Figure 2B and 2F). Accordingly, no significant differences were observed in the density of control and mutant retinal vasculature ( Figure 2G ). Vascular outgrowth is dependent not only on endothelial proliferation, but also on appropriate sprouting activity of ECs through the sensing of angiogenic factors such as VEGF-A. 29, 30 Therefore, we assessed the number of sprouts and filopodia in Esm1 KO mice. Despite its tip cell-specific expression in the retina, Esm1 does not play a role in tip-stalk cell specification because no difference was observed in sprout number between Esm1 WT and Esm1 KO mice. However, a significant decrease in filopodia number was observed in mutants relatively to control littermates ( Figure 2C , 2H, and 2I), suggesting that the impaired vascular progression in the absence of Esm1 might be attributable to decreased motility of endothelial sprouts.
To better understand the role of Esm1 in tip cell behavior, we generated a novel transgenic mouse line, Esm1(BAC) iCreERT2 , where tamoxifen-inducible iCreERT2 was inserted into a large genomic clone downstream of the Esm1 promoter (Online Figure IA) . The resulting mouse line was interbred with
mT/mG double transgenics, and recombination was induced by administrating 4-hydroxytamoxifen 24 hours before analysis. In the retinas of these animals, recombined green fluorescent protein (GFP)-positive cells were mostly restricted to sprouting ECs similar to the distribution of endogenous Esm1 protein (compare Online Figure IB with Figure 1A ). By combining this novel genetic tool with the Esm1 KO mouse line, we labeled retinal sprouts in the presence or absence of Esm1. Recombination was induced at P4, and retinas were analyzed at P5. The ratio of GFP-positive sprouts remained unaltered between Esm1 WT and Esm1 KO retinas, which further supports that Esm1 is not required for tip-stalk cell interconversion ( Figure 2J and 2K). Although the recombination pattern was similar between Esm1 WT and Esm1 KO retinas, we observed that GFP-positive cells were found in small, contiguous clusters in Esm1 KO retinas, whereas recombined cells were scattered and rarely touching each other in Esm1 WT samples. Quantification of the GFP-positive areas, which may represent isolated GFP-positive or several GFP-positive cells in direct contact, confirmed that significantly larger patches were found in Esm1 KO 
Absence of Esm1 Impairs Leukocyte Extravasation at the Transmigration Step
Suggesting a possible role in inflammation, Esm1 expression is also induced by inflammatory cytokines. 2, 3 In fact, in vitro data indicated that Esm1 inhibits leukocyte extravasation by inhibiting their adhesion to ECs. 6 To investigate this question in vivo, we performed peritonitis assays on Esm1-deficient and control mice. Contrary to the expected, Esm1 KO mice showed a significant decrease in leukocyte extravasation when compared with control littermates ( Figure 3A) . Leukocyte extravasation was also assessed in venules of the cremaster muscle by intravital microscopy, which allows direct visualization and analysis of leukocyte behavior during the rolling, adhesion, and transmigration steps. 32 Although hemodynamic parameters are similar between control and Esm1 KO mice (Online Table I ), the decreased leukocyte extravasation observed in Esm1 KO mice was solely attributable to reduced transmigration ( Figure 3B-3D) . These results argue against a prominent role of Esm1 in leukocyte-EC adhesion in this model and suggested that Esm1 might act on EC junctions. Immunostainings for adherens and tight junctions, however, uncovered no significant structural differences between Esm1 WT and Esm1 KO mice (Online Figure II) .
Esm1 Is Specifically Required for VEGF-A 165 -Induced VP
Because leukocyte extravasation was compromised in Esm1 KO mice at the transmigration step, we questioned whether Esm1 KO mice might present a general defect in VP. To this end, we performed the Miles assay by injecting different permeability-inducing agents subcutaneously. Both histamine and VEGF-A 121 induced a robust and undistinguishable increase in VP both in Esm1 WT and Esm1 KO mice, whereas the increase in VEGF-A 165 -induced permeability was significantly reduced in Esm1 KO mice compared with controls ( Figure 3E ). Coinjection of Esm1 and VEGF-A 165 had no effect on the increase in permeability in Esm1 WT mice when compared with VEGF-A 165 stimulation alone. However, the decreased VEGF-A 165 -induced permeability response in Esm1 KO animals was rescued by coinjection of Esm1 and VEGF-A 165 ( Figure 3F ).
VEGF Signaling Is Decreased In Vivo in the Absence of Esm1
To test whether VEGF signaling is compromised in Esm1 KO mutants, we performed immunostaining for p-Erk1/2, a well-established downstream effector of VEGF signaling, in P5 retinas. p-Erk1/2 immunostaining was most intense in endothelial sprouts ( Figure 4A ) in line with high activity of the VEGF pathway in tip cells. To confirm the specificity of the p-Erk1/2 immunostaining, P5 pups were administered a highly selective inhibitor for MEK1/2 (U0126), a kinase that activates Erk1/2 through phosphorylation. U0126-treated pups showed a pronounced decrease in p-Erk1/2 immunostaining in the retinal angiogenic front ( Figure 4B ). Western blot analysis of lung lysates from the same pups confirmed the decreased Erk1/2 phosphorylation ( Figure 4C ). 
In Esm1
KO retinas, p-Erk1/2 immunostaining remained stronger in sprouts compared with ECs in the adjacent plexus, but the difference in staining intensity was significantly decreased (Figure 4D-4F) . Activity of the VEGF pathway was also assessed by injecting VEGF-A 165 intraperitoneally and analyzing VEGFR2 phosphorylation in lung lysates. Although control pups showed a robust increase in VEGFR2 phosphorylation at 30 minutes after VEGF-A 165 injection, only a comparably weak effect was obtained in Esm1 KO pups ( Figure 4G ). Taken together, these results suggested KO mice showed reduced polymorphonuclear leukocytes (PMNs) extravasation at both 2 and 4 hours after interleukin (IL)-1β-induced inflammation of the peritoneum. B to D, Analysis of leukocyte extravasation through intravital microscopy of the cremaster muscle shows that reduced PMN extravasation observed in Esm1 KO mice is attributable to impaired transmigration (D) and not rolling (B), nor adhesion (C) to the endothelium (n>40 venules from a total of 6 mice per genotype). E, Miles assay performed on dorsal skin shows that Esm1 KO that ECs are less responsive to VEGF-A in the absence of Esm1 in vivo.
Decreased Tumor Angiogenesis in Esm1 KO Mice
Esm1 plasma levels are increased in several pathological conditions including cancer, [8] [9] [10] [11] [12] [13] [14] and inhibition of Esm1 has been described to reduce tumor growth. 15, 16 It is however not known whether this involves alterations in tumor angiogenesis. Esm1 expression in tumors was observed throughout most ECs ( Figure 1B and Online Figure IC) , suggesting that it may play a prominent role in tumor angiogenesis.
We used syngeneic tumor models in Esm1 WT and Esm1 KO mice, in which Lewis lung carcinoma or melanoma (B16F1) cells were inoculated on their flanks. Tumor growth was monitored during 2 weeks, and angiogenesis was evaluated at the end point. With the exception of a transient delay in Lewis lung carcinoma tumor growth at 12 days postinoculation, no significant difference in tumor growth was observed when comparing Esm1 KO with control mice ( Figure 5A ). To evaluate the effect of Esm1 on tumor angiogenesis, tumor sections were immunostained with an EC marker, CD31 or Endomucin, and vessel density was quantified.
Esm1
KO mice presented a 30% decrease in vessel density in both tumor types when compared with control mice (Figure 5B-5D ). Thus, Esm1 plays a more prominent role in tumor vascularization than in developmental angiogenesis possibly because of its broader expression pattern in the tumor vasculature.
Absence of Esm1 Leads to Decreased Brain Edema Upon Ischemic Stroke
Altered VP is a hallmark of many pathological situations such as ischemic stroke. It is well established that the breakdown of the blood-brain barrier is a determining factor in the acute phase of stroke, because it leads to edema and increased neural lesions. We have shown that Esm1 plays a role in VP, and therefore we questioned whether this would hold true in the context of ischemic stroke.
Because Esm1 plasma levels are increased in several pathological conditions, we quantified Esm1 levels in plasma of mice before and 24 hours after the induction of ischemic stroke by transient middle cerebral artery occlusion. Circulating Esm1 was increased by 25% upon ischemic stroke ( Figure 5E ). MRI was performed for each mouse 24 hours after middle cerebral artery occulsion and edema-corrected lesion volumes and the affected hemisphere space-occupying effect (%HSE) attributable to brain edema were quantified. A striking 50% decrease in both parameters was observed in Esm1 KO mice when compared with controls ( Figure 5F-5H ).
Esm1 Modulates VEGF-A 165 Bioavailability by Competing With It for Fibronectin Binding
To uncover the molecular mechanisms by which Esm1 modulates VEGF signaling, we tried to identify endothelial Esm1-binding partners. For this purpose, a murine Esm1 construct carrying a C-terminal FLAG-tag was overexpressed in human embryonic kidney 293 cells cells to produce Esm1-FLAGenriched supernatant that was added to HUVEC, allowing binding of Esm1 to putative membrane and extracellular binding partners. Esm1-FLAG was then immunoprecipitated ( Figure 6A ), and samples were analyzed by mass spectrometry. Because Esm1 is a secreted protein, only coimmunoprecipitated membrane and extracellular proteins that were found with ≥10 times more abundance in the Esm1-FLAG sample compared with the control (based on tandem mass spectrometry [MS/MS] count differences for each protein) were considered as putative interacting partners. Several extracellular but no membrane proteins were coimmunoprecipitated with Esm1 and detected by mass spectrometry (Online Table II) .
Interestingly, 2 of the putative interacting partners, fibronectin and heparan sulfate proteoglycan 2 (HSPG2), have been previously described to modulate VEGF-A signaling [33] [34] [35] [36] and are also involved in the regulation of VP. [37] [38] [39] It is well established that VEGF-A binds heparin and heparan sulfate, including those residues present in HSPG2. 33, 40 Both in vitro and in vivo experiments have shown that HSPG2 positively regulates VEGF-A signaling and helps to establish VEGF gradients that act on angiogenic ECs. 41 HSPG2 also modulates the binding of VEGF-A to its receptors. 33, 42 The interaction between fibronectin and VEGF has also been reported to enhance VEGF signaling in vivo, namely to increase EC migration. 35 Therefore, we reasoned that the interaction between Esm1 and KO mice (n>60 sections; 6 mice/genotype). E to H, Analysis of control and Esm1 KO 24 hours after transient middle cerebral artery occlusion. E, Esm1 protein levels in serum. F, Representative T2-weight MRI images of hyperintense ischemic areas (outlined in red). G, Quantification of edemacorrected lesion volumes (LVc). H, Quantification of the affected hemisphere space-occupying effect (%HSE) attributable to brain edema. *P<0.05; ***P<0.001, Student t test. WT indicates wild type.
one or both of these proteins might influence VEGF-A signaling. Starved and confluent HUVEC monolayers were stimulated by adding VEGF-A 165 together, or not, with Esm1 to serum-free medium ( Figure 6B ). Stimulation with Esm1 alone did not lead to appreciable VEGFR2 phosphorylation. Upon VEGF-A 165 stimulation, phospho-VEGFR2 levels were only slightly altered by addition of recombinant Esm1 ( Figure 6B ). Next, we mimicked an extracellular matrix microenvironment composed of fibronectin, HSPG2, and VEGF-A in the absence or presence of Esm1 ( Figure 6C ). Although fibronectin is well known to activate integrins, no difference in the levels of p-FAK (phospho-focal adhesion kinase), a key downstream effector of activated integrins, [43] [44] [45] was observed (Online Figure  IIIA) . Accordingly, no difference was observed between Esm1 KO and control littermate retinas immunostained for activated-integrin β1 and phospho-paxillin (Online Figure IIIB and IIIC). We did however find that HUVEC seeded on wells coated with fibronectin, HSPG2, and VEGF-A contained consistently higher levels of phospho-VEGFR2 in the absence of Esm1 ( Figure 6C ). Because this result suggested that the presence of Esm1 might negatively regulate VEGF presentation by matrix components, we next tested whether Esm1 might displace extracellular matrix-bound VEGF-A 165 . Measurement of VEGF-A 165 levels in the coating supernatant showed that free VEGF-A 165 increased in the presence Esm1 in a dosedependent manner ( Figure 6D ), indicating that Esm1 inhibits matrix interactions of VEGF-A 165 . This finding was further supported by strongly increased levels of phospho-VEGFR2 when HUVEC monolayers were stimulated with the supernatant from Esm1-treated wells (Online Figure IVA) . When the same experiments were performed with VEGF-A 121 , which lacks C-terminal matrix-binding motifs, both the levels of VEGF-A 121 in the supernatant and of phospho-VEGFR2 in supernatant-treated HUVEC were independent of Esm1 (Online Figure IVA and IVB) .
To elucidate whether the effect of Esm1 on VEGF signaling is mediated by fibronectin or HSPG2, each of these components was withdrawn from the coating mixture. The ability of Esm1 to increase the bioavailability of VEGF-A 165 5-fold was not significantly changed by the removal of HSPG2. In contrast, removal of fibronectin strongly increased the levels of VEGF-A 165 in supernatants and reduced the difference between Esm1-treated and untreated samples ( Figure 6E ). This finding indicates that Esm1 displaces fibronectin-bound VEGF-A 165 .
Finally, to confirm Esm1 binding to fibronectin, a solid phase binding ELISA assay was performed. VEGF-A 165 and VEGF-A 121 were used as positive and negative controls, respectively. 25, 35, 40, 46 Incubation of increasing concentrations of Esm1 with fibronectin-coated wells resulted in a binding curve with a clear saturation point, thus confirming the ability of Esm1 to bind directly to fibronectin ( Figure 6F ). Although fibronectin has been shown to bind several growth factors including PDGF-BB, 25 we observed a decrease of up to ≈20% in fibronectin-bound VEGF-A 165 but not of PDGF-BB when in the presence of Esm1 (Online Figure IVC) . Moreover, when assaying the effect of Esm1 on EC migration by performing scratch wound assays on HUVEC stimulated with several growth factors that interact with fibronectin, we observed that Esm1 only affected VEGF-A 165 -mediated EC migration (Online Figure IVD and IVE) . This further supports our previous conclusion that Esm1 specifically displaces fibronectinbound VEGF-A 165 .
Discussion
The present study demonstrates that Esm1 modulates VEGF-A 165 -driven biological processes in vivo, namely angiogenesis and VP. Esm1 is a dermatan sulfate proteoglycan that is expressed and secreted mostly by ECs. 1 Its regulation by both angiogenic factors and cytokines suggested that it might play a role in both angiogenesis and inflammation. [2] [3] [4] [5] Nevertheless, in vivo evidence for an Esm1 role in either of these biological processes was lacking. In this study, we confirm, through the use of mouse genetics and chemical inhibitors, that Esm1 expression is regulated by VEGF-A but not VEGF-C in vivo. Our findings also establish that Esm1 regulates angiogenesis and inflammation in vivo in both physiological and pathological contexts, albeit to different extents.
Previous in vitro reports established that Esm1 binds to the LFA-1 complex on leukocytes and thereby inhibits the adhesion of leukocytes to intercellular adhesion molecule 1. 6 Therefore, it was postulated that Esm1 might block leukocyte extravasation. Contrary to this prediction, we now found that Esm1 is necessary for leukocyte extravasation in vivo. Furthermore, visualization and analysis of the distinct steps of leukocyte extravasation through intravital microscopy establish that Esm1 does not interfere with the adhesion of leukocytes to the endothelium but instead exerts its effect at the transmigration level. Moreover, Esm1 KO mice have a specific decrease in VEGF-A 165 -induced VP.
Our results point toward the existence of a positive feedback loop where VEGF-A positively regulates Esm1 expression, which in turn enhances VEGF-A-mediated signaling ( Figure 7) . Although recent work has suggested the existence of such positive feedback loop for VEGF signaling in vitro, 47 the underlying mechanisms remained unclear. We now identify fibronectin and HSPG2 as potential interactors of Esm1, which are known to regulate VEGF signaling and bind to VEGF-A 165 but not VEGF-A 121 . 25, 35, 40, 46 Moreover, fibronectin and HSPG2 have also been implicated in the regulation of vessel permeability. fibronectin mutants are embryonic lethal and, among several other defects, display hemorrhages. 37, 38 Plasma fibronectin, which is mostly present postnatally, is a negative regulator of VP. Likewise, mice deficient in endothelial heparan sulfate also have reduced permeability. 39 Although heparan sulfate does not bind VEGF-A 121 , it was shown that these endothelial heparan sulfate-deficient mice displayed reduced VEGF-A 165 -and VEGF-A 121 -induced VP because heparan sulfate also binds VEGFR2 and thereby modulates ligand-receptor binding affinities. The finding that VEGF-A 121 -induced VP is regulated by heparan sulfate and not by Esm1 further supports that HSPG2 is not a relevant interaction partner of Esm1, which is in agreement with our in vitro data. Instead, we propose that Esm1 positively modulates VEGF-A 165 signaling by binding to fibronectin and preventing the sequestration of VEGF-A 165 by fibronectin. This increases the bioavailability of VEGF-A 165 and consequently to increased levels of VEGFR2 signaling.
Esm1 KO mice were born with normal Mendelian ratios and are viable and fertile. Accordingly, we found that Esm1 plays a minor role in sprouting and angiogenesis. However, more prominent and potentially disease-relevant functions of Esm1 have been uncovered in the current study. Esm1 regulates tumor angiogenesis as well as VEGF-induced VP, which is known to occur in several pathological conditions. For instance, in ischemic stroke, increased levels of VEGF are beneficial for postischemic angiogenesis and recovery; however, in the acute phase, increased levels of VEGF enhance VP and thereby neuronal damage. [48] [49] [50] Therefore, inhibition of Esm1 might be an attractive therapeutical/preventive strategy, for high stroke risk populations, to modulate the effects of VEGF-A on VP. Moreover, Esm1 blockage in cancer may contribute not only to antiangiogenic effects but also to decreased cancer cell dissemination, because the hyperpermeable character of tumor vessels are known to facilitate this process.
• Endothelial cell -specific molecule 1 (Esm1) is secreted by endothelial cells, and it is regulated by both inflammatory cytokines and proangiogenic factors in vitro. • Esm1 plasma levels are increased in pathological situations such as sepsis, and several cancer types, and its overexpression in tumorigenic cancer cells induces tumor growth.
• In vitro evidence points toward a role of Esm1 in inhibiting leukocyte extravasation by blocking LFA-1/intercellular adhesion molecule 1 interactions.
What New Information Does This Article Contribute?
• Esm1 positively regulates angiogenesis, leukocyte extravasation, and vascular permeability in both physiological and pathological contexts.
• Esm1 interacts directly with fibronectin, leading to displacement of fibronectin-bound vascular endothelial growth factor-A 165 (VEGF-A 165 ), increased bioavailability of VEGF-A 165 and consequently increased VEGF signaling.
For more than a decade, Esm1 has been associated with angiogenesis and inflammation. However, in vivo evidence for a role of Esm1 in either of these processes was lacking. We now provide the first in vivo data showing that Esm1 positively regulates angiogenesis, inflammation, and vascular permeability. The generation of the Esm1 knockout and Esm1(BAC) iCreERT2 reporter mouse lines has enabled us to show that Esm1 impacts developmental and tumor angiogenesis by regulating VEGF-induced endothelial cell migration. Contrary to the current belief in the field, Esm1 does not inhibit leukocyte extravasation, instead our in vivo data shows that it promotes leukocyte extravasation at the transmigration step. We also show that in the absence of Esm1 function, VEGF-A 165 -induced vascular permeability is reduced, leading to a 50% decrease in lesion volume on cerebral ischemia. Mechanistically, we show that Esm1, a target of VEGF-A itself, increases VEGF-A 165 bioavailability and consequently VEGF signaling by binding to fibronectin and displacing fibronectin-bound VEGF-A 165 . Altogether our results render Esm1 as an attractive therapeutic target to modulate the effects of VEGF-A in pathological conditions, namely as a preventive strategy for high stroke risk populations and also in cancer where Esm1 blockage may prevent VEGF-induced angiogenesis and cancer cell dissemination.
Novelty and Significance
